Results 181 to 190 of about 27,061 (270)

HTLV tax and Mycosis Fungoides [PDF]

, 1993
Bette A. Pancake, Dorothea Zucker‐Franklin   +1 more
openalex   +1 more source

"Missed" Diagnosis of Mycosis Fungoides: A Case Report. [PDF]

Clin Case Rep
Mathur M, Thakur N, Regmi S, Paudel S, Karki S, Bhattarai N.   +5 more
europepmc   +1 more source

Squamous cell carcinoma appearing in X-ray-treated mycosis fungoides

, 1977
G Volden, TE. Larsen
openalex   +2 more sources

? Mycosis Fungoides [PDF]

Proceedings of the Royal Society of Medicine, 1933
openaire   +1 more source

GATA3 as a Prognostic Marker in Early-Stage Classical Mycosis Fungoides: Association With Disease Progression and Survival Outcomes. [PDF]

Cancer Med
Wen P, Li F, Xie Y, Chen W, Wang T, Zhuo X, Wang L.   +6 more
europepmc   +1 more source

Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group

, 1979
Laura Molin, K Thomsen, G Volden
openalex   +2 more sources

Spanning 17 Years: Diagnostic Evolution from Lichen Planus Pigmentosus to Hyperpigmented Mycosis Fungoides. [PDF]

Clin Cosmet Investig Dermatol
Zha W, Lu J.
europepmc   +1 more source

Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis [PDF]

, 1995
David Fivenson, Brian J. Nickoloff
openalex   +1 more source

Downregulation of miRNA-590 and miRNA-182 in Early-Stage Mycosis Fungoides in Skin of Color Patients. [PDF]

Cureus
Mahmoud RH, El-Khalawany M, Abdelghani R, Fawzi SK, Ayoub SE, Mohamed NE.   +5 more
europepmc   +1 more source

British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015 [PDF]

, 2016
Abel EA, Berg M, Berg M, Bhatnagar A, Bilsland D, Bjellerup M, Calzavara‐Pinton PG, Chen X, Cox AJ, Deleu H, Diffey BL, Freeman K, George SA, Gilchrest BA, Grattan CE, Hannuksela M, Hönigsmann H, Jansén CT, Jansén CT, Jeanmougin M, Joint Formulary Committee, Kao CL, Kivanc MT, Lassus A, Leonard F, LeVine MJ, Lindelöf B, Maravić N, Margolis D, Marguery MC, Marsland AM, Mastalier U, Mathews‐Roth MM, McFadden N, McGeorge BC, Molin L, Morison WL, Neumann NJ, Norris PG, Park YM, Pirner K, Pothiawala SZ, Reymond JL, Roelandts R, Roelandts R, Roelandts R, Roenigk HH, Ros AM, Ros AM, Rosén K, Rosén K, Rosén K, Rübben A, Sheehan‐Dare RA, Stadler R, Stern RS, Takashima A, Tegner E, Tegner E, Thomsen K, Turjanmaa K, Viander M, Vázquez‐López F, Weelden H, Wennersten G, Wilkinson JD   +65 more
core   +2 more sources